Get a Sample
Schedule a MeetingJuly 2025
The global exosome therapeutics market size was calculated at USD 789.37 thousand in 2024 and is predicted to increase from USD 928.93 thousand in 2025 to approximately USD 4,020.75 thousand by 2034, expanding at a CAGR of 17.68% from 2025 to 2034. The global exosome therapeutics market is witnessing robust growth driven by the increasing prevalence of chronic, infectious, autoimmune, and neurodegenerative diseases, rapid advancements in exosome isolation, and rising investments in healthcare infrastructure. This report covers market trends, production volumes, technological developments, and competitive dynamics across North America, Europe, and APAC between 2025 and 2030.
The increasing demand from oncology, neurology, cardiovascular diseases, and regenerative medicine is anticipated to boost the expansion of the exosome therapeutics market during the forecast period. Exosomes are being engineered as natural drug delivery systems due to their ability to cross biological barriers, low immunogenicity, and potential for targeted therapy. The exosome therapeutics market refers to the development and commercialization of therapies that utilize exosomes—nano-sized extracellular vesicles secreted by cells, to deliver biomolecules such as proteins, RNA, and lipids for disease treatment.
In the rapidly evolving technological landscape, Artificial intelligence emerges as a game-changer and holds potential for growth and innovation in the exosome therapeutics market by optimizing drug discovery, enhancing the personalization of treatments, and accelerating the analysis of exosome data. The integration of AI has the potential to create more precise, data-driven exosome therapies. AI algorithms can efficiently and accurately analyze large datasets to identify potential therapeutic targets and design more effective exosome-based therapies. AI models analyze multi-omics and exosome biomarker data to predict a patient's ability to respond to specific therapies. AI assists in tailoring exosome therapies based on individual patient profiles by accurately analyzing their unique data, which leads to more personalized treatment strategies for better outcomes.
In March 2024, VivaZome Therapeutics Pty Ltd and La Trobe University announced their collaboration to explore the therapeutic potential of VivaZome’s extracellular vesicles (EVs) in models of stroke in the laboratory of Professor Chris Sobey. This collaborative effort brings together VivaZome’s expertise in EV manufacturing and La Trobe’s stroke research capabilities, led by Professor Sobey. The study entitled “Anti-inflammatory exosomes for stroke: a proof-of-concept (PoC) pilot study” is supported by a $300k grant from the La Trobe Proof-of-Concept (PoC) Fund. (Source: https://vivazome.com)
In December 2024, EXO Biologics and its CDMO subsidiary, ExoXpert, leading innovators in exosome-based therapeutics and drug delivery solutions, announced that ExoXpert is the first European CDMO specializing in exosomes to receive Good Manufacturing Practice (GMP) certification for its state-of-the-art manufacturing plant. In addition, EXO Biologics has managed to achieve the loading of GMP-grade exosomes with mRNA and DNA payloads, a major milestone for the development of exosome-based therapies. (Source: https://www.exobio.be)
In May 2025, RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease.
(Source: https://www.prweb.com)
| Report Coverage | Details |
| Market Size in 2024 | USD 789.37 Thousand |
| Market Size in 2025 | USD 928.93 Thousand |
| Market Size by 2034 | USD 4,020.75 Thousand |
| Market Growth Rate from 2025 to 2034 | CAGR of 17.68% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Source, Therapeutic Application, Delivery Mechanism, Technology, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key player | Date | Breakthroughs |
| Coya Therapeutics, Inc | In August 2025 | Coya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing biologics, announced that the U.S. Food and Drug Administration had accepted its Investigational New Drug (IND) application for COYA 302. This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis (ALS). (Source: https://ir.coyatherapeutics.com) |
| Aegle Therapeutics Corp. | In August 2024 | Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle (EV) therapies to address immune and inflammatory-based dermatological disorders, announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102 for the treatment of the rare pediatric skin blistering disease DEB. (Source: https://www.prnewswire.com) |
| Capricor Therapeutics | In August 2025 | In August 2025, Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, announced that the first subjects had been dosed in a Phase 1 clinical trial evaluating its StealthX exosome-based vaccine. The study, funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services’ Project NextGen, follows review and clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The trial is being conducted by an NIAID-funded network of clinical trial sites. (Source: https://www.globenewswire.com) |
| EXO Biologics | In June 2024 | EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, today announces it has completed dosing of the first cohort of patients in EVENEW. This EVENEW study is the first European Medicines Agency (EMA) authorized clinical trial involving mesenchymal stromal cell (MSC)-based exosomes. |
| RION | In September 2025 | RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP) biologic platform in I&I and will advance PEP Biologic into Phase 3 clinical development for advanced tissue regeneration and immune-mediated dermatologic indications. |
Which Segment Is Dominating the Market by Source in the Exosome Therapeutics Market?
The mesenchymal stem cells (MSCs) segment dominated the global exosome therapeutics market with a 45% share in 2024. Several studies are increasingly focused on the therapeutic potential of MSC-derived exosomes as a cell-free therapeutic for various health conditions, such as neurological disorders, autoimmune diseases, cardiovascular diseases, cancer, and tissue repair.
On the other hand, the dendritic cells segment is expected to witness remarkable growth during the forecast period. Dendritic cell-derived exosomes (Dex) are highly valued for their use in cancer vaccines and anti-infective therapies, owing to their potent antigen-presenting capabilities. Dex is promising for developing cancer vaccines and therapies against infectious diseases, along with the rapid advancements in 3D cell culture, which significantly increases Dex yield, driving the segment’s growth in the coming years.
What causes the intravenous (IV) segment to dominate the exosome therapeutics market?
The intravenous (IV) segment held a dominant presence in the exosome therapeutics market with a 55% share in 2024. Intravenous (IV) administration is the most widely used method for delivering exosome-based therapies, which allows for systemic circulation to reach target tissues.
On the other hand, the intranasal segment is expected to grow at a notable rate. Intranasal delivery of exosomes shows significant promise owing to their ability to cross the blood-brain barrier, leading to potential treatments for various chronic diseases. This delivery route has the potential to treat neurological disorders and inflammatory conditions by providing targeted therapeutic effects.
How Did the Oncology Segment Dominate the Exosome Therapeutics Market in 2024?
The oncology segment held the majority share of the exosome therapeutics market with a 40% share in 2024. The growth of the segment is driven by the rising global burden of cancer, particularly solid tumors and hematological malignancies. Exosomes act as drug transporters, offering innovative strategies for targeted drug delivery in cancer therapy. Exosomes can deliver therapeutic payloads specifically to cancer cells, enhancing efficacy and reducing side effects. The rapid advancements in exosome isolation and drug delivery technologies, and rising R&D efforts, are expected to propel the segment’s growth during the forecast period.
On the other hand, the neurology segment is projected to grow at a CAGR between 2025 and 2034. The growth of the segment is driven by the increasing prevalence of Alzheimer’s disease, Parkinson’s disease, and stroke globally. Significant investment from pharmaceutical companies, a surge in the number of clinical trials, including Phase I/II and early Phase III, and expanding academic-industry collaborations, are accelerating the development and commercialization of exosome-based therapies for various conditions in neurology.
How Will Isolation & Purification Technologies Segment Dominate the Market for Exosome Therapeutics in 2024?
The isolation & purification technologies segment held the dominant share of 35% in the exosome therapeutics market. Isolation and purification techniques enable the extraction of higher-purity and consistent exosomes for various therapeutic applications, including cancer vaccines, tissue regeneration, immunotherapy, and others. Key isolation methods include ultracentrifugation, size-exclusion chromatography (SEC), immunoaffinity capture, and microfluidics-based techniques.
On the other hand, the engineering technologies segment is anticipated to grow notably during the forecast period. Engineering technologies include surface modification and cargo loading. Engineered exosomes showing significant potential in treating autoimmune, cancer, neurodegenerative, and cardiovascular diseases by delivering treatments more effectively and safely.
The U.S. exosome therapeutics market size was evaluated at USD 284.17 thousand in 2024 and is projected to be worth around USD 1,472.70 thousand by 2034, growing at a CAGR of 17.88% from 2025 to 2034.
What Made North America Dominate the Market for Exosome Therapeutics in 2024?
In 2024, North America held a dominant presence in the market. This region holds a strong position in exosome therapeutics, with the presence of thriving biotechnology companies, accelerating emphasis on healthcare spending, surging R&D investments by key players, and increasing clinical trials for cancer immunotherapy, neurodegenerative diseases, and wound healing. The increasing prevalence of cancer, autoimmune diseases, infectious diseases, and neurodegenerative diseases like Alzheimer’s Disease, Parkinson’s Disease, and others, along with the rapid advancement in exosome collection technologies. Innovative methods, like immunoaffinity capture, microfluidic devices, and continuous-flow systems, enable more efficient exosome isolation and purification from complex samples, which is expected to accelerate the market’s revenue during the forecast period.
The United States is a major contributor to the growth of the exosome therapeutics market. The presence of modern research institutions and biotechnology companies in the country, like Aegle Therapeutics, Capricor Therapeutics, StemXO Therapeutics, Codiak BioSciences, Coya Therapeutics, EV Therapeutics, and Direct Biologics. The country has a well-established healthcare infrastructure, a surge in clinical trials, increasing investment in advanced therapies, rising cases of chronic diseases, growing demand for personalized medicine, high per capita healthcare expenditure, expanding applications of exosome therapeutics, and increasing regulatory approvals.
On the other hand, the Asia Pacific region is expected to experience the fastest growth during the forecast period. The market in the Asia Pacific is expanding steadily, driven by developing healthcare infrastructure, rising government funding for exosome-based therapies, increasing advancements in biotechnology, reimbursement policies, and a surge in regulatory approvals. Moreover, the greater R&D spending by major players and the increasing number of clinical studies are likely to boost the expansion of the exosome therapeutics market in the region.
The increasing burden of chronic diseases and growing focus on precision medicine in the region create significant medical needs and offer substantial market growth opportunities for innovative therapies. Several key players in the market are strategically adopting initiatives such as mergers & acquisitions to strengthen their market presence. The market is witnessing rapid advancements in exosome technologies are anticipated to propel the growth of the exosome therapeutics market in the region by improving exosome isolation and purification, expanding their potential in regenerative medicine, and enhancing their use as targeted drug delivery vehicles. Such factors are paving the way for more effective and targeted treatments and broadening possibilities of exosome therapeutics in the region.
By Source
By Therapeutic Application
By Delivery Mechanism
By Technology
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
July 2025
May 2025
August 2024
October 2024